Pretreatment Resistance to Hepatitis C Virus Protease Inhibitors Boceprevir/Telaprevir in Hepatitis C Subgenotype 1A-Infected Patients from Manitoba

Andonov Anton; Kadkhoda Kamran; Osiowy Carla; Kaita Kelly

首页> 外文期刊>ISRN Hypertension >Pretreatment Resistance to Hepatitis C Virus Protease Inhibitors Boceprevir/Telaprevir in Hepatitis C Subgenotype 1A-Infected Patients from Manitoba

【24h】

Pretreatment Resistance to Hepatitis C Virus Protease Inhibitors Boceprevir/Telaprevir in Hepatitis C Subgenotype 1A-Infected Patients from Manitoba

机译：来自曼尼托巴省的丙型肝炎亚型1A感染患者对丙型肝炎病毒蛋白酶抑制剂Boceprevir / Telaprevir的预处理抗性

获取原文

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

BACKGROUND Traditional therapy with pegylated interferon and ribavirin combined with the new protease inhibitors boceprevir or telaprevir has demonstrated improved outcomes in hepatitis C virus (HCV)-infected patients. Prevalence data regarding pre-existing drug-resistant variants to these two new virus inhibitors in the Canadian population are not available.

机译：背景技术用聚乙二醇化干扰素和利巴韦林与新的蛋白酶抑制剂博西泼韦或特拉普韦联合的传统疗法已证明在丙型肝炎病毒（HCV）感染的患者中改善了预后。目前尚无关于加拿大人群中针对这两种新病毒抑制剂的现有耐药变体的流行率数据。

著录项

来源
《ISRN Hypertension》 |2013年第7期|共3页
作者
Andonov Anton; Kadkhoda Kamran; Osiowy Carla; Kaita Kelly;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种
中图分类心血管疾病;
关键词

相似文献

外文文献
中文文献
专利

1. Pretreatment resistance to hepatitis C virus protease inhibitors boceprevir/telaprevir in hepatitis C subgenotype 1a-infected patients from Manitoba [J] . AndonovA., KadkhodaK., OsiowyC., Canadian journal of gastroenterology . 2013,第7期

机译：来自曼尼托巴省的丙型肝炎亚型1a感染患者对丙型肝炎病毒蛋白酶抑制剂boceprevir / telaprevir的预处理耐药性
2. Specific Detection of Naturally Occurring Hepatitis C Virus Mutants with Resistance to Telaprevir and Boceprevir (Protease Inhibitors) among Treatment-Na?ve Infected Individuals [J] . Salvador Fonseca-Coronado, Alejandro Escobar-Gutiérrez, Karina Ruiz-Tovar, Journal of Clinical Microbiology . 2012,第2期

机译：在未接受过治疗的感染个体中特异性检测对特拉普韦和博西普韦（蛋白酶抑制剂）具有耐药性的天然丙型肝炎病毒突变体
3. Analysis of long-term persistence of resistance mutations within the hepatitis C virus NS3 protease after treatment with telaprevir or boceprevir. [J] . Susser S, Vermehren J, Forestier N, Journal of clinical virology: The official publication of the Pan American Society for Clinical Virology . 2011,第4期

机译：使用telaprevir或boceprevir治疗后，丙型肝炎病毒NS3蛋白酶内耐药突变的长期持久性分析。
4. Peptide-based protease inhibitors of the hepatitis C virus full-length NS3 protein (protease-helices/NTPase) [C] . Anja Johansson, Eva Akerblom, Gunnar Lindeberg, European Peptide Symposium . 2002

机译：基于肽的蛋白质蛋白酶抑制剂甲型肝炎病毒全长NS3蛋白（蛋白酶 - 螺旋/ NTPAse）
5. Drug resistance mechanisms and drug design strategies for human immunodeficiency virus and hepatitis C virus proteases [D] . Wang, Yong 2012

机译：人类免疫缺陷病毒和丙型肝炎病毒蛋白酶的耐药机制和药物设计策略
6. Pretreatment resistance to hepatitis C virus protease inhibitors boceprevir/telaprevir in hepatitis C subgenotype 1a-infected patients from Manitoba [O] . Anton Andonov, Kamran Kadkhoda, Carla Osiowy, 2013

机译：曼尼托巴省丙型肝炎亚型1a感染患者对丙型肝炎病毒蛋白酶抑制剂boceprevir / telaprevir的预处理耐药性
7. Specific Detection of Naturally Occurring Hepatitis C Virus Mutants with Resistance to Telaprevir and Boceprevir (Protease Inhibitors) among Treatment-Naive Infected Individuals [O] . S. Fonseca-Coronado, A. Escobar-Gutierrez, K. Ruiz-Tovar, 2011

机译：特异性检测具有抗Teladrevir和Boceprevir（蛋白酶抑制剂）的耐受抗卵巢的丙型肝炎病毒突变体在治疗 - 天真感染的个体中

Pretreatment Resistance to Hepatitis C Virus Protease Inhibitors Boceprevir/Telaprevir in Hepatitis C Subgenotype 1A-Infected Patients from Manitoba

摘要

著录项

相似文献

相关主题

期刊订阅